Heron Therapeutics, Inc.HRTXNASDAQ
LOADING
|||
Switch Symbol:
Operating Income Growth Under Pressure
Below historical average, modest growth trend.
Left:
||||
Year-over-year operating income growth rate
Latest
-150.03%
↓ 3836% below average
Average (39q)
-3.81%
Historical baseline
Range
High:193.61%
Low:-151.90%
CAGR
+3.6%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -150.03% |
| Q2 2025 | -151.90% |
| Q1 2025 | -24.42% |
| Q4 2024 | 193.61% |
| Q3 2024 | 30.83% |
| Q2 2024 | -34.33% |
| Q1 2024 | 53.05% |
| Q4 2023 | 59.00% |
| Q3 2023 | 41.21% |
| Q2 2023 | -28.25% |
| Q1 2023 | -62.43% |
| Q4 2022 | 51.40% |
| Q3 2022 | 15.39% |
| Q2 2022 | 21.34% |
| Q1 2022 | -17.53% |
| Q4 2021 | -3.54% |
| Q3 2021 | 14.49% |
| Q2 2021 | -16.03% |
| Q1 2021 | 14.98% |
| Q4 2020 | -4.99% |
| Q3 2020 | -4.73% |
| Q2 2020 | -5.72% |
| Q1 2020 | 11.17% |
| Q4 2019 | -70.32% |
| Q3 2019 | 32.69% |
| Q2 2019 | 19.97% |
| Q1 2019 | -26.09% |
| Q4 2018 | -22.82% |
| Q3 2018 | -7.53% |
| Q2 2018 | 25.27% |
| Q1 2018 | 16.00% |
| Q4 2017 | -49.80% |
| Q3 2017 | 1.76% |
| Q2 2017 | 14.69% |
| Q1 2017 | -5.33% |
| Q4 2016 | 1.95% |
| Q3 2016 | -10.84% |
| Q2 2016 | -29.28% |
| Q1 2016 | -7.25% |
| Q4 2015 | -38.10% |